name stringlengths 3 26 | slug stringlengths 3 22 | aliases stringlengths 9 99 | is_peptide stringclasses 2
values | fda_approved stringclasses 2
values | brand_names stringclasses 6
values | approval_year float64 1.98k 2.02k ⌀ | compounding_503a stringlengths 126 870 | bulks_503b stringlengths 70 313 | shortage_list stringclasses 4
values | wada_prohibited stringclasses 3
values | dea_schedule stringclasses 1
value | notes stringlengths 135 243 | sources stringlengths 1.05k 1.9k | last_verified stringdate 2026-11-09 00:00:00 2026-11-09 00:00:00 | page_url stringlengths 44 63 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AOD-9604 | aod-9604 | AOD9604; Tyr-hGH 177-191; AOD-9604 acetate | yes | no | null | null | Nomination withdrawn or removed. Nominations withdrawn; FDA reviewed it on its own and its advisory committee voted 12 to 0 against adding it to the 503A bulks list on Dec 4, 2024. FDA's safety risk page (updated Apr 22, 2026) lists it under nominated but withdrawn. | Not nominated. Not on FDA's 503B categories list (updated March 21, 2025). | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. FDA advisers voted 12 to 0 against adding it to the 503A bulks list on Dec 4, 2024. | FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks | 2026-04-22 ;; FDA briefing document: AOD-9604, PCAC December 4, 2024 | https://www.fda... | 2026-11-09 | https://livingpluspeptides.com/peptides/aod-9604/ |
BPC-157 | bpc-157 | Body Protection Compound 157; BPC 157; PL 14736; PCO-02; Bepecin; BPC-157 acetate | yes | no | null | null | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval). On HHS's interim enforcement policy (Appendix A), released Oct 28, 2026 as a draft, with public comments open until Nov 13, 2026. HHS does not intend to take action against a state-licens... | Not nominated. Not listed in any 503B category on FDA's 503B list updated March 21, 2025. | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. Since Oct 28, 2026 it is covered by HHS's draft interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and B) | https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf | 2026-10-28 ;; Federal Register: HHS notice of availability, FR Doc. 2026-22192 (filed Oct ... | 2026-11-09 | https://livingpluspeptides.com/peptides/bpc-157/ |
Bremelanotide (PT-141) | bremelanotide-pt-141 | PT-141; Vyleesi; Bremelanotide acetate | yes | yes | Vyleesi | 2,019 | Component of an FDA-approved drug. Active ingredient of Vyleesi (NDA 210557, approved June 21, 2019). No FDA 503A category list names bremelanotide. A 2020 FDA warning letter (inspection in 2018, before approval) listed it as ineligible. | Not nominated. Not on the FDA 503B nominated substances list (updated March 21, 2025). | Not on the shortage list | no | not scheduled | Approved June 21, 2019 as Vyleesi (NDA 210557), with no record in the FDA drug shortage database. FDA treats products sold online as PT-141 as unapproved new drugs. | DailyMed: VYLEESI label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf | 2025-11-13 ;; FDA: Vyleesi approval package, NDA 210557 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf | 2019-06-21 ;; Drugs@FDA: NDA 210557 | https://www.access... | 2026-11-09 | https://livingpluspeptides.com/peptides/bremelanotide-pt-141/ |
Cagrilintide | cagrilintide | CagriSema (with semaglutide) | yes | no | null | null | Not nominated. Not listed in any 503A nomination category (list updated May 14, 2026). FDA states cagrilintide cannot be used in compounding under federal law and is not a component of an FDA-approved drug (page current Oct 1, 2026). | Not nominated. Not listed in FDA's 503B nomination categories (updated Mar 21, 2025). FDA says it cannot be used in compounding under federal law. | Not on the shortage list | unclear | not scheduled | Investigational, with no FDA-approved product and no FDA shortage record. FDA states it cannot be used in compounding under federal law (page current Oct 1, 2026). | FDA: Concerns with unapproved GLP-1 drugs used for weight loss | https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss | 2026-10-01 ;; FDA: Bulk drug substances nominated under section 503A (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-1... | 2026-11-09 | https://livingpluspeptides.com/peptides/cagrilintide/ |
CJC-1295 | cjc-1295 | CJC-1295 DAC; CJC-1295 with DAC; DAC:GRF; CJC-1295 without DAC; Tetra-substituted GRF (1-29) | yes | no | null | null | Nomination withdrawn or removed. Nominations withdrawn; FDA lists CJC-1295 under 'nominated but withdrawn' from category 2 (page current as of April 22, 2026), with safety concerns stated. Not in any 503A category on the May 14, 2026 list. PCAC voted against inclusion on December 4, 2024. | Not nominated. Not in any 503B category (list updated March 21, 2025). | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. FDA advisers voted against adding it to the 503A bulks list on Dec 4, 2024. | FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks | 2026-04-22 ;; FDA: PCAC briefing document, CJC-1295, December 4, 2024 | https://www.fd... | 2026-11-09 | https://livingpluspeptides.com/peptides/cjc-1295/ |
Epitalon | epitalon | Epithalon; Ala-Glu-Asp-Gly; AEDG peptide; Epitalon acetate | yes | no | null | null | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval). On HHS's interim enforcement policy (Appendix A), released Oct 28, 2026 as a draft, with public comments open until Nov 13, 2026. HHS does not intend to take action against a state-licens... | Not nominated. Not on FDA's 503B categories list (updated March 21, 2025). FDA says no outsourcing facility has reported compounding epitalon. | Not on the shortage list | unclear | not scheduled | Not FDA approved and not in the FDA drug shortage database. Since Oct 28, 2026 it is covered by HHS's draft interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and B) | https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf | 2026-10-28 ;; Federal Register: HHS notice of availability, FR Doc. 2026-22192 (filed Oct ... | 2026-11-09 | https://livingpluspeptides.com/peptides/epitalon/ |
GHK-Cu | ghk-cu | Copper peptide; Copper tripeptide-1; Glycyl-L-histidyl-L-lysine copper; GHK | yes | no | null | null | Category 1 (may be compounded while FDA evaluates). Non-injectable routes only: removed from Category 1 on April 22, 2026 after nominators withdrew, then to be added back after a May 5, 2026 clarification (list updated May 14, 2026). Injectable GHK-Cu is on the 'nominated but withdrawn' list. PCAC consult planned befor... | Not nominated. Not on the FDA 503B nominated substances list (updated March 21, 2025). | Not on the shortage list | unclear | not scheduled | Not an FDA-approved drug and not in the FDA drug shortage database. Non-injectable GHK-Cu is back in 503A Category 1 (list updated May 14, 2026), with an advisory committee review planned before the end of February 2027. | FDA: 503A nominated bulk drug substances categories (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-14 ;; FDA: Certain bulk drug substances that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-si... | 2026-11-09 | https://livingpluspeptides.com/peptides/ghk-cu/ |
GHRP-2 and GHRP-6 | ghrp-2-ghrp-6 | GHRP-2; GHRP-6; Pralmorelin; Growth hormone releasing peptide-2; Growth hormone releasing peptide-6 | yes | no | null | null | Category 3 (nominated without enough support). Both GHRP-2 and GHRP-6 are in 503A category 3 (nominated without adequate support) on FDA's list updated May 14, 2026. | Category 2 (significant safety concerns). Status differs by route: GHRP-6, and GHRP-2 for injectable and nasal routes, are in 503B category 2 (significant safety risks, added September 29, 2023); GHRP-2 for other routes is in 503B category 1 (under evaluation). List updated March 21, 2025. | Not on the shortage list | yes | not scheduled | Neither GHRP-2 nor GHRP-6 is FDA approved, and neither is in the FDA drug shortage database. Both are in 503A Category 3, and both are in 503B Category 2 (GHRP-2 only for injectable and nasal routes). | FDA: Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-14 ;; FDA: Bulk drug substances nominated for use in compounding under section 503B (updated March 21, 2025) | https://www.fda.gov/media/94164/download | 2025-03-21 ;... | 2026-11-09 | https://livingpluspeptides.com/peptides/ghrp-2-ghrp-6/ |
Ipamorelin | ipamorelin | Ipamorelin acetate; Ipamorelin free base | yes | no | null | null | Nomination withdrawn or removed. 503A nominations withdrawn September 19, 2024; FDA lists it as nominated but withdrawn from category 2. Not in any 503A category on the May 14, 2026 list. PCAC voted 0-12-1 against inclusion on October 29, 2024. | Category 2 (significant safety concerns). Ipamorelin acetate is in 503B category 2 (significant safety risks) since September 29, 2023 (list updated March 21, 2025). | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. FDA advisers voted against adding it to the 503A bulks list on Oct 29, 2024, and it is in 503B Category 2. | FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks | 2026-04-22 ;; FDA: PCAC briefing document, ipamorelin, October 29, 2024 | https://www.... | 2026-11-09 | https://livingpluspeptides.com/peptides/ipamorelin/ |
Kisspeptin | kisspeptin | Kisspeptin-10; Kisspeptin-54; Metastin; KiSS-1 peptide | yes | no | null | null | Category 2 (significant safety concerns). Kisspeptin-10 added September 29, 2023; still Category 2 on the FDA list updated May 14, 2026. PCAC voted 0 to 11 against the 503A bulks list on October 29, 2024. | Not nominated. Not on the FDA 503B nominated substances list (updated March 21, 2025). | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. Kisspeptin-10 has been in 503A Category 2 (significant safety risks) since Sept 29, 2023. | FDA: 503A nominated bulk drug substances categories (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-14 ;; FDA: Certain bulk drug substances that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-si... | 2026-11-09 | https://livingpluspeptides.com/peptides/kisspeptin/ |
KPV | kpv | Lysine-proline-valine; Lys-Pro-Val; alpha-MSH (11-13); KPV acetate | yes | no | null | null | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval). On HHS's interim enforcement policy (Appendix A), released Oct 28, 2026 as a draft, with public comments open until Nov 13, 2026. HHS does not intend to take action against a state-licens... | Not nominated. Not listed in any 503B category on FDA's 503B list updated March 21, 2025. | Not on the shortage list | unclear | not scheduled | Not FDA approved and not in the FDA drug shortage database. Since Oct 28, 2026 it is covered by HHS's draft interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and B) | https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf | 2026-10-28 ;; Federal Register: HHS notice of availability, FR Doc. 2026-22192 (filed Oct ... | 2026-11-09 | https://livingpluspeptides.com/peptides/kpv/ |
Liraglutide | liraglutide | Victoza; Saxenda | yes | yes | Victoza; Saxenda; Liraglutide injection, generic | 2,010 | Component of an FDA-approved drug. Active ingredient of approved drugs. FDA's shortage database still listed liraglutide injection as currently in shortage (first posted Jul 18, 2023; entries updated Oct 14, 2026). | FDA proposed not to include. FDA proposed not to include liraglutide on the 503B bulks list (Federal Register May 1, 2026; comment period extended to July 30, 2026 by a Jun 26, 2026 notice). No final decision found as of Oct 25, 2026. Liraglutide remained on the FDA shortage list, which is a separate 503B route. | Currently in shortage. Liraglutide injection is listed as currently in shortage, first posted July 18, 2023, with entries updated through Oct 14, 2026. Saxenda is listed as available until discontinuation in January 2027. | no | not scheduled | First approved Jan 25, 2010 as Victoza. Liraglutide injection is still listed as a current FDA shortage (first posted July 18, 2023), and FDA proposed keeping it off the 503B bulks list (May 1, 2026). | FDA: Drug Shortages database, liraglutide injection | https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c | 2026-10-25 ;; FDA: FDA approves first generic of once-daily GLP-1 injection (Dec 23, 2024) | https://www.fda.gov/news-events/press-announcements/fd... | 2026-11-09 | https://livingpluspeptides.com/peptides/liraglutide/ |
LL-37 | ll-37 | Cathelicidin LL-37; Human cathelicidin; hCAP18 (precursor); FALL-39; Ropocamptide; CAMP | yes | no | null | null | Nomination withdrawn or removed. Not in category 1, 2 or 3 on FDA's 503A list updated May 14, 2026; FDA's safety page (current as of April 22, 2026) lists cathelicidin LL-37 as previously in category 2 with the nomination withdrawn. Not discussed at the July 2026 PCAC meeting. | Not nominated. Not listed in any 503B category on FDA's 503B list updated March 21, 2025. | Not on the shortage list | unclear | not scheduled | Not FDA approved and not in the FDA drug shortage database. FDA lists cathelicidin LL-37 as a withdrawn former 503A Category 2 substance. | FDA: Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-14 ;; FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bu... | 2026-11-09 | https://livingpluspeptides.com/peptides/ll-37/ |
Melanotan II | melanotan-ii | MT-II; MT2; Melanotan 2 | yes | no | null | null | Nomination withdrawn or removed. Listed by FDA as 'nominated but withdrawn' from 503A Category 2 (page current April 22, 2026); FDA still lists safety concerns. FDA plans a PCAC meeting before end of February 2027 that will discuss Melanotan II for the 503A bulks list. | Not nominated. Not on the FDA 503B nominated substances list (updated March 21, 2025). | Not on the shortage list | unclear | not scheduled | Not FDA approved and not in the FDA drug shortage database. Its 503A Category 2 nomination was withdrawn, and an FDA advisory committee review is planned before the end of February 2027. | FDA: Certain bulk drug substances that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks | 2026-04-22 ;; FDA: Upcoming Pharmacy Compounding Advisory Committee meeting | https://www.fda.gov/advisory-co... | 2026-11-09 | https://livingpluspeptides.com/peptides/melanotan-ii/ |
MK-677 (Ibutamoren) | mk-677 | Ibutamoren; Ibutamoren mesylate; MK-0677; L-163,191 | no | no | null | null | Category 2 (significant safety concerns). 503A category 2 since Sept 29, 2023, still listed on FDA's May 14, 2026 categories list. FDA's advisory committee voted 13 to 1 against adding it to the 503A bulks list on Oct 29, 2024. | Category 2 (significant safety concerns). 503B category 2 (significant safety risks) since Dec 29, 2022, per FDA's safety risk page; also listed on FDA's 503B categories list (updated March 21, 2025). | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. Ibutamoren mesylate is in Category 2 (significant safety risks) for both 503A and 503B compounding. | FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks | 2026-04-22 ;; FDA: 503A categories list (updated May 14, 2026) | https://www.fda.gov/m... | 2026-11-09 | https://livingpluspeptides.com/peptides/mk-677/ |
MOTS-c | mots-c | Mitochondrial open reading frame of the 12S rRNA-c; MOTS-c acetate; MOTs-C | yes | no | null | null | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval). On HHS's interim enforcement policy (Appendix A), released Oct 28, 2026 as a draft, with public comments open until Nov 13, 2026. HHS does not intend to take action against a state-licens... | Not nominated. Not on FDA's 503B categories list (updated March 21, 2025). | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. Since Oct 28, 2026 it is covered by HHS's draft interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and B) | https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf | 2026-10-28 ;; Federal Register: HHS notice of availability, FR Doc. 2026-22192 (filed Oct ... | 2026-11-09 | https://livingpluspeptides.com/peptides/mots-c/ |
Oxytocin | oxytocin | Pitocin; Oxytocin injection, USP | yes | yes | Pitocin; Oxytocin Injection, USP generic | 1,980 | Component of an FDA-approved drug. Active ingredient of FDA-approved Pitocin (NDA 018261) and oxytocin injection (NDA 018248). | Under evaluation (Category 1). 503B Category 1 (under evaluation), marked as a component of FDA-approved drugs, on the FDA list updated March 21, 2025. | Not on the shortage list | no | not scheduled | 1980 is the earliest oxytocin approval shown in Drugs@FDA (Syntocinon, NDA 018245, Apr 17, 1980), recorded as a new formulation or new manufacturer, so older approvals may not be listed there. No record in the FDA drug shortage database. | DailyMed: PITOCIN label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad | 2026-05-05 ;; DailyMed: Oxytocin Injection, USP label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c | 2026-01-12 ;; Drugs@FDA: NDA 018261 (Pitocin) ... | 2026-11-09 | https://livingpluspeptides.com/peptides/oxytocin/ |
Retatrutide | retatrutide | LY3437943 | yes | no | null | null | Not nominated. Not listed in any 503A nomination category (list updated May 14, 2026). FDA states retatrutide cannot be used in compounding under federal law and is not a component of an FDA-approved drug (page current Oct 1, 2026). | Not nominated. Not listed in FDA's 503B nomination categories (updated Mar 21, 2025). FDA says it cannot be used in compounding under federal law. | Not on the shortage list | unclear | not scheduled | Investigational, with no FDA-approved product and no FDA shortage record. FDA states it cannot be used in compounding under federal law (page current Oct 1, 2026). | FDA: Concerns with unapproved GLP-1 drugs used for weight loss | https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss | 2026-10-01 ;; FDA: Bulk drug substances nominated under section 503A (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-1... | 2026-11-09 | https://livingpluspeptides.com/peptides/retatrutide/ |
Selank | selank | Selank acetate; TP-7; Thr-Lys-Pro-Arg-Pro-Gly-Pro | yes | no | null | null | Nomination withdrawn or removed. FDA's safety risk page (updated Apr 22, 2026) lists selank acetate (TP-7) under nominated but withdrawn (previously in category 2). Not in any category on FDA's May 14, 2026 503A list. | Not nominated. Not on FDA's 503B categories list (updated March 21, 2025). | Not on the shortage list | unclear | not scheduled | Not FDA approved and not in the FDA drug shortage database. Its 503A nomination was withdrawn, and it was not on the July 2026 advisory committee agenda. | FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks | 2026-04-22 ;; FDA: 503A categories list (updated May 14, 2026) | https://www.fda.gov/m... | 2026-11-09 | https://livingpluspeptides.com/peptides/selank/ |
Semaglutide | semaglutide | Ozempic; Wegovy; Rybelsus; Wegovy HD | yes | yes | Ozempic injection; Wegovy injection and tablets; Rybelsus and Ozempic tablets | 2,017 | Component of an FDA-approved drug. Shortage resolved Feb 21, 2025; 503A grace period ended after the Apr 24, 2025 court ruling. FDA does not intend to act on four or fewer essentially-copy prescriptions per month (page current Apr 1, 2026). | FDA proposed not to include. FDA proposed not to include semaglutide on the 503B bulks list (Federal Register May 1, 2026; comment period extended to July 30, 2026 by a Jun 26, 2026 notice). No final decision found as of Oct 25, 2026. Not on the drug shortage list. | Shortage resolved. FDA declared the semaglutide injection shortage resolved Feb 21, 2025. The shortage database now lists only Rybelsus tablets (3, 7 and 14 mg) as to be discontinued (posted June 4, 2026), to be replaced by Ozempic tablets. | no | not scheduled | First approved Dec 5, 2017 as Ozempic. FDA declared the injection shortage resolved Feb 21, 2025, and proposed keeping semaglutide off the 503B bulks list (May 1, 2026). | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize | 2026-04-01 ;; FDA: FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks li... | 2026-11-09 | https://livingpluspeptides.com/peptides/semaglutide/ |
Semax | semax | ACTH(4-10) analog; ACTH(4-7)PGP; Semax acetate; Met-Glu-His-Phe-Pro-Gly-Pro | yes | no | null | null | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval). On HHS's interim enforcement policy (Appendix A), released Oct 28, 2026 as a draft, with public comments open until Nov 13, 2026. HHS does not intend to take action against a state-licens... | Not nominated. Not on FDA's 503B categories list (updated March 21, 2025). FDA reports no outsourcing facility has reported compounding Semax since 2019. | Not on the shortage list | unclear | not scheduled | Not FDA approved and not in the FDA drug shortage database. Since Oct 28, 2026 it is covered by HHS's draft interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and B) | https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf | 2026-10-28 ;; Federal Register: HHS notice of availability, FR Doc. 2026-22192 (filed Oct ... | 2026-11-09 | https://livingpluspeptides.com/peptides/semax/ |
Sermorelin | sermorelin | Sermorelin acetate; Geref; GHRH (1-29); GRF 1-29 | yes | no | null | 1,990 | Component of an FDA-approved drug. Not in any 503A category on FDA's list updated May 14, 2026. FDA's 503B list marks sermorelin acetate as a component of an FDA-approved drug (Geref, discontinued). FDA found in 2013 that Geref was not withdrawn for safety or effectiveness reasons. FDA has not said how the 2009 withdra... | Under evaluation (Category 1). Sermorelin acetate is in 503B category 1, marked as a component of an FDA-approved drug (list updated March 21, 2025). | Not on the shortage list | yes | not scheduled | First approved Dec 28, 1990 as Geref (NDA 019863); Geref was later discontinued and its approvals withdrawn, and FDA determined in 2013 that it was not withdrawn for safety or effectiveness reasons. No record in the FDA drug shortage database. | Federal Register 2013-04827: Geref not withdrawn for safety or effectiveness (FDA) | https://public-inspection.federalregister.gov/2013-04827.pdf | 2013-03-04 ;; Drugs@FDA: NDA 019863 (Geref) | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863 | 2026-10-25 ;; Drugs@FDA: NDA ... | 2026-11-09 | https://livingpluspeptides.com/peptides/sermorelin/ |
TB-500 and Thymosin Beta-4 | tb-500-thymosin-beta-4 | TB-500; TB500; Thymosin beta-4 fragment (LKKTETQ); Ac-LKKTETQ; Thymosin beta-4; Tβ4; RGN-259 | yes | no | null | null | HHS interim enforcement policy (may be compounded under its conditions while FDA writes the 503A bulks list rule; not FDA approval). On HHS's interim enforcement policy (Appendix A), released Oct 28, 2026 as a draft, with public comments open until Nov 13, 2026. HHS does not intend to take action against a state-licens... | Not nominated. Neither TB-500 nor thymosin beta-4 appears in any 503B category on FDA's 503B list updated March 21, 2025. | Not on the shortage list | yes | not scheduled | Not FDA approved and not in the FDA drug shortage database. Since Oct 28, 2026 it is covered by HHS's draft interim enforcement policy for 503A compounding while FDA decides, by rulemaking, whether to add it to the 503A bulks list. | HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and B) | https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf | 2026-10-28 ;; Federal Register: HHS notice of availability, FR Doc. 2026-22192 (filed Oct ... | 2026-11-09 | https://livingpluspeptides.com/peptides/tb-500-thymosin-beta-4/ |
Tesamorelin | tesamorelin | Tesamorelin acetate; Egrifta; Egrifta SV; Egrifta WR; TH9507 | yes | yes | Egrifta WR; Egrifta SV | 2,010 | Biologic, not eligible for 503A compounding. Active ingredient of FDA-approved Egrifta. The application was deemed a BLA on March 23, 2020; FDA says biological products that transitioned that day are not eligible for the 503A compounding exemptions. | Biologic, not eligible for 503B compounding. Deemed a BLA on March 23, 2020; FDA says transitioned biological products are not eligible for the 503B exemptions. Not in any 503B category (list updated March 21, 2025). | Not on the shortage list | yes | not scheduled | First approved Nov 10, 2010 as Egrifta, and regulated as a biologic since March 23, 2020, which FDA says makes it ineligible for 503A and 503B compounding. No record in the FDA drug shortage database. | Drugs@FDA: BLA 022505 (Egrifta) | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505 | 2026-10-25 ;; FDA: Egrifta WR supplement approval letter, March 25, 2025 | https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022505Orig1s020ltr.pdf | 2025-03-25 ;; FDA: Notice t... | 2026-11-09 | https://livingpluspeptides.com/peptides/tesamorelin/ |
Thymosin Alpha-1 | thymosin-alpha-1 | Thymalfasin; Ta1; Tα1; Thymosin alpha 1 acetate; Zadaxin | yes | no | null | null | Nomination withdrawn or removed. Not in category 1, 2 or 3 on FDA's 503A list updated May 14, 2026; FDA lists Ta1 as previously in category 2 with the nomination withdrawn. At the Dec 4, 2024 PCAC meeting FDA proposed NOT adding it and the committee voted 4 yes, 17 no for both the free base and the acetate. | Category 3 (nominated without enough support). Listed in 503B category 3 (nominated without adequate support) on FDA's 503B list updated March 21, 2025. | Not on the shortage list | no | not scheduled | Not FDA approved and not in the FDA drug shortage database. FDA advisers voted 17 to 4 against adding it to the 503A bulks list on Dec 4, 2024. | FDA: Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026) | https://www.fda.gov/media/94155/download | 2026-05-14 ;; FDA: Certain bulk drug substances for use in compounding that may present significant safety risks | https://www.fda.gov/drugs/human-drug-compounding/certain-bu... | 2026-11-09 | https://livingpluspeptides.com/peptides/thymosin-alpha-1/ |
Tirzepatide | tirzepatide | Mounjaro; Zepbound; LY3298176 | yes | yes | Mounjaro; Zepbound | 2,022 | Component of an FDA-approved drug. Shortage resolved Oct 2, 2024 (re-affirmed Dec 19, 2024); 503A grace period ended after the Mar 5, 2025 court ruling. FDA does not intend to act on four or fewer essentially-copy prescriptions per month (page current Apr 1, 2026). | FDA proposed not to include. FDA proposed not to include tirzepatide on the 503B bulks list (Federal Register May 1, 2026; comment period extended to July 30, 2026 by a Jun 26, 2026 notice). No final decision found as of Oct 25, 2026. Not on the drug shortage list. | Shortage resolved. FDA declared the tirzepatide injection shortage resolved Dec 19, 2024, after re-evaluating its Oct 2, 2024 determination. No current record in the FDA shortage database. | no | not scheduled | First approved May 13, 2022 as Mounjaro. FDA declared the injection shortage resolved Dec 19, 2024, and proposed keeping tirzepatide off the 503B bulks list (May 1, 2026). | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize | 2026-04-01 ;; FDA: FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks li... | 2026-11-09 | https://livingpluspeptides.com/peptides/tirzepatide/ |
FDA Peptide Status Tracker and Warning Letters
FDA approval, compounding, shortage, WADA and DEA status for peptides, plus FDA warning letters that name them. Published by Living+ Peptides (https://livingpluspeptides.com), an education-only reference site. Updated 2026-11-13.
Files
peptide-status-tracker.csv(26 rows): one row per peptide. FDA approval, 503A and 503B compounding status, FDA drug shortage status, WADA status, DEA schedule, notes, the sources checked and the date each row was last verified. Same data as the Status Tracker page: https://livingpluspeptides.com/regulation/tracker/fda-peptide-warning-letters.csv(173 rows): one row per FDA warning letter whose text names a peptide in the tracker. Letter date, posted date, firm, FDA's subject line, issuing office, the peptides named, and the link to FDA's copy. Same list as https://livingpluspeptides.com/regulation/warning-letters/
How it is made
The tracker is checked against primary sources (FDA, the Federal Register, WADA and DEA) and every row carries its sources and a last verified date. The warning letter list is built from FDA's warning letter search: a letter is listed only when FDA's matching text contains the peptide's name. Firm names, dates and subject lines are copied from FDA. A warning letter is FDA's notice that it believes a firm broke the law; it is not a court ruling.
This is education only, not medical or legal advice. Statuses change; check the linked sources before relying on a row.
License and credit
CC BY 4.0. Please credit "Living+ Peptides" and link to https://livingpluspeptides.com/regulation/tracker/
Corrections: https://livingpluspeptides.com/corrections/
- Downloads last month
- 153